201 related articles for article (PubMed ID: 32964347)
1. The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data.
Maric GD; Pekmezovic TD; Mesaros ST; Tamas OS; Ivanovic JB; Martinovic VN; Andabaka MM; Jovanovic AL; Veselinovic ND; Kisic-Tepavcevic DB; Drulovic JS
Neurol Sci; 2021 May; 42(5):1887-1893. PubMed ID: 32964347
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes.
Ciampi E; Uribe-San-Martin R; Soler B; Molnar K; Reyes D; Keller K; Carcamo C
Mult Scler Relat Disord; 2020 Nov; 46():102565. PubMed ID: 33039942
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Tettey P; Siejka D; Simpson S; Taylor B; Blizzard L; Ponsonby AL; Dwyer T; van der Mei I
Neuroepidemiology; 2016; 46(2):106-13. PubMed ID: 26784322
[TBL] [Abstract][Full Text] [Related]
4. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes.
Diržiuvienė B; Mickevičienė D
Mult Scler Relat Disord; 2022 Mar; 59():103558. PubMed ID: 35123292
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients.
Abbatemarco JR; Ontaneda D; Nakamura K; Husak S; Wang Z; Alshehri E; Bermel RA; Conway DS
Mult Scler Relat Disord; 2020 Nov; 46():102593. PubMed ID: 33296988
[TBL] [Abstract][Full Text] [Related]
6. Impact of comorbidities on the disability progression in multiple sclerosis.
Maric G; Pekmezovic T; Tamas O; Veselinovic N; Jovanovic A; Lalic K; Mesaros S; Drulovic J
Acta Neurol Scand; 2022 Jan; 145(1):24-29. PubMed ID: 34414566
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Neurol; 2017 Jul; 17(1):134. PubMed ID: 28716070
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
Salter A; Lancia S; Kowalec K; Fitzgerald KC; Marrie RA
Neurology; 2024 Mar; 102(5):e209135. PubMed ID: 38350062
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.
Hua LH; Hersh CM; Tian F; Mowry EM; Fitzgerald KC
Mult Scler Relat Disord; 2021 Jan; 47():102637. PubMed ID: 33276238
[TBL] [Abstract][Full Text] [Related]
10. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
Thormann A; Magyari M; Koch-Henriksen N; Laursen B; Sørensen PS
J Neurol; 2016 Dec; 263(12):2484-2493. PubMed ID: 27699465
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of comorbidities in patients with multiple sclerosis using administrative data from 2007 to 2016 in Iran.
Amiri Z; Azmin M; Amiri S; Akbarisari A; Sahraian MA; Farzadfar F; Soleymani F
Mult Scler Relat Disord; 2023 Jun; 74():104693. PubMed ID: 37031549
[TBL] [Abstract][Full Text] [Related]
12. Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry.
Stanikić M; Salmen A; Chan A; Kuhle J; Kaufmann M; Ammann S; Schafroth S; Rodgers S; Haag C; Pot C; Kamm CP; Zecca C; Gobbi C; Calabrese P; Manjaly ZM; von Wyl V;
Mult Scler Relat Disord; 2022 Nov; 67():104084. PubMed ID: 35933756
[TBL] [Abstract][Full Text] [Related]
13. Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
Kowalec K; McKay KA; Patten SB; Fisk JD; Evans C; Tremlett H; Marrie RA;
Neurology; 2017 Dec; 89(24):2455-2461. PubMed ID: 29117961
[TBL] [Abstract][Full Text] [Related]
14. The epidemiology of comorbidities among multiple sclerosis patients in northeastern Poland.
Kapica-Topczewska K; Tarasiuk J; Chorąży M; Czarnowska A; Brola W; Szczepański M; Kochanowicz J; Kułakowska A
Mult Scler Relat Disord; 2020 Jun; 41():102051. PubMed ID: 32197130
[TBL] [Abstract][Full Text] [Related]
15. Vascular comorbidities in the onset and progression of multiple sclerosis.
Tettey P; Simpson S; Taylor BV; van der Mei IA
J Neurol Sci; 2014 Dec; 347(1-2):23-33. PubMed ID: 25454639
[TBL] [Abstract][Full Text] [Related]
16. Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.
Lo LMP; Taylor BV; Winzenberg T; Palmer AJ; Blizzard L; van der Mei I
J Neurol; 2021 Feb; 268(2):602-612. PubMed ID: 32880720
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study.
Roshanisefat H; Bahmanyar S; Hillert J; Olsson T; Montgomery S
Eur J Neurol; 2014 Nov; 21(11):1353-e88. PubMed ID: 25041631
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of malignant diseases in patients with multiple sclerosis: population-based MS Registry data.
Maric G; Pekmezovic T; Mesaros S; Tamas O; Veselinovic N; Budimkic Stefanovic M; Jovanovic A; Drulovic J
Neurol Sci; 2022 Dec; 43(12):6839-6846. PubMed ID: 36040558
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and anxiety adversely affect cognition in multiple sclerosis.
Marrie RA; Patel R; Figley CR; Kornelsen J; Bolton JM; Graff L; Mazerolle EL; Marriott JJ; Bernstein CN; Fisk JD;
Mult Scler Relat Disord; 2019 Jan; 27():164-170. PubMed ID: 30384203
[TBL] [Abstract][Full Text] [Related]
20. Epilepsy in multiple sclerosis: A nationwide population-based register study.
Burman J; Zelano J
Neurology; 2017 Dec; 89(24):2462-2468. PubMed ID: 29117950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
